Adrian Towse
Adrian Towse
Office of Health Economics
Verifierad e-postadress på ohe.org - Startsida
Citeras av
Citeras av
Differential pricing for pharmaceuticals: reconciling access, R&D and patents
PM Danzon, A Towse
International journal of health care finance and economics 3, 183-205, 2003
Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing …
LP Garrison Jr, A Towse, A Briggs, G de Pouvourville, J Grueger, PE Mohr, ...
Value in health 16 (5), 703-719, 2013
Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report
ML Berger, N Dreyer, F Anderson, A Towse, A Sedrakyan, SL Normand
Value in Health 15 (2), 217-230, 2012
The R&D cost of a new medicine
J Mestre-Ferrandiz, J Sussex, A Towse
Monograph, 2012
Learning from Thailand's health reforms
A Towse, A Mills, V Tangcharoensathien
Bmj 328 (7431), 103-105, 2004
Variability of cost‐effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability
M Barbieri, M Drummond, R Willke, J Chancellor, B Jolain, A Towse
Value in health 8 (1), 10-23, 2005
Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics and outcomes research: a …
E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, ...
Value in Health 15 (8), 1162-1171, 2012
A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report [7]
LP Garrison Jr, PJ Neumann, RJ Willke, A Basu, PM Danzon, JA Doshi, ...
Value in Health 21 (2), 161-165, 2018
Value‐based differential pricing: Efficient prices for drugs in a global context
P Danzon, A Towse, J Mestre‐Ferrandiz
Health economics 24 (3), 294-301, 2015
Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement
PM Danzon, AW Mulcahy, AK Towse
Health economics 24 (2), 238-252, 2015
Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products
A Towse, LP Garrison
Pharmacoeconomics 28, 93-102, 2010
Operationalizing value-based pricing of medicines: a taxonomy of approaches
J Sussex, A Towse, N Devlin
Pharmacoeconomics 31 (1), 1-10, 2013
Cost-effectiveness thresholds: economic and ethical issues
CP Towse, N Devlin
Office of Health Economics, 2002
Should NICE’s threshold range for cost per QALY be raised? Yes
A Towse
Bmj 338, 2009
Gene therapy: evidence, value and affordability in the US health care system
G Hampson, A Towse, SD Pearson, WB Dreitlein, C Henshall
Journal of comparative effectiveness research 7 (1), 15-28, 2018
Using QALYs in cancer: a review of the methodological limitations
M Garau, KK Shah, AR Mason, Q Wang, A Towse, MF Drummond
Pharmacoeconomics 29, 673-685, 2011
Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis
LP Garrison Jr, S Kamal-Bahl, A Towse
Value in Health 20 (2), 213-216, 2017
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare
B Jönsson, G Hampson, J Michaels, A Towse, JMG von der Schulenburg, ...
The European journal of health economics 20, 427-438, 2019
The economics of gene therapy and of pharmacogenetics
P Danzon, A Towse
Value in Health 5 (1), 5-13, 2002
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
A Towse, CK Hoyle, J Goodall, M Hirsch, J Mestre-Ferrandiz, JH Rex
Health Policy 121 (10), 1025-1030, 2017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20